

Valrie Boige

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6136506/valerie-boige-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

26

papers

496

citations

10

h-index

22

g-index

30

ext. papers

657

ext. citations

4

avg, IF

3.11

L-index

#	Paper	IF	Citations
26	Hepatocellular carcinoma: French Intergroup Clinical Practice Guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, AFEF, SIAD, SFR/FRI). <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021 , 45, 101590	2.4	2
25	Bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: A meta-analysis of individual patients' data from 3 phase III studies. <i>Cancer Treatment Reviews</i> , 2021 , 97, 102202	14.4	4
24	Intratumor CMS Heterogeneity Impacts Patient Prognosis in Localized Colon Cancer. <i>Clinical Cancer Research</i> , 2021 , 27, 4768-4780	12.9	5
23	Hepatic arterial infusion of chemotherapy as an option in a multimodal treatment of metastatic squamous cell carcinoma of the anus. <i>European Journal of Cancer</i> , 2021 , 142, 147-149	7.5	2
22	Palliation of dysphagia in metastatic oesogastric cancers: An international multidisciplinary position. <i>European Journal of Cancer</i> , 2020 , 135, 103-112	7.5	1
21	Predictive factors for early progression during induction chemotherapy and chemotherapy-free interval: analysis from PRODIGE 9 trial. <i>British Journal of Cancer</i> , 2020 , 122, 957-962	8.7	2
20	Treatment intensification with hepatic arterial infusion chemotherapy in patients with liver-only colorectal metastases still unresectable after systemic induction chemotherapy - a randomized phase II study -- SULTAN UCGI 30/PRODIGE 53 (NCT03164655)- study protocol. <i>BMC Cancer</i> , 2020 , 20, 1-11	4.8	1
19	Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiation in patients with locally advanced rectal cancer: Final results of PRODIGE 23 phase III trial, a UNICANCER GI trial.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 4007-4007	2.2	81
18	Role of precision medicine for patients with advanced biliary tract cancers.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 552-552	2.2	
17	Sorafenib Plus Irinotecan Combination in Patients With RAS-mutated Metastatic Colorectal Cancer Refractory To Standard Combined Chemotherapies: A Multicenter, Randomized Phase 2 Trial (NEXIRI-2/PRODIGE 27). <i>Clinical Colorectal Cancer</i> , 2020 , 19, 301-310.e1	3.8	3
16	Chemotherapy beyond immune checkpoint inhibitors in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2020 , 137, 117-126	7.5	8
15	The cellular prion protein controls the mesenchymal-like molecular subtype and predicts disease outcome in colorectal cancer. <i>EBioMedicine</i> , 2019 , 46, 94-104	8.8	17
14	Bevacizumab (BV) maintenance (M) after first-line chemotherapy (CT) plus BV for metastatic colorectal cancer (mCRC) patients (pts): A meta-analysis of individual pts data (IPD) from three phase III studies.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3550-3550	2.2	1
13	Express study: A trial in progress exploring the association between low level of genomic alteration and exceptional and unexpected response to targeted therapies in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3159-TPS3159	2.2	
12	PRODIGE 53-UCGI 30 (SULTAN): A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non-resectable. <i>Journal of Clinical Oncology</i> , 2019 , 37, TPS3159-TPS3159	2.2	
11	Aspirin versus placebo in stage III or high-risk stage II colon cancer with PIK3CA mutation: A French randomised double-blind phase III trial (PRODIGE 50-ASPIK). <i>Digestive and Liver Disease</i> , 2018 , 50, 305-307	3.3	10
10	Peritoneal and extraperitoneal relapse after previous curative treatment of peritoneal metastases from colorectal cancer: What survival can we expect?. <i>European Journal of Cancer</i> , 2018 , 100, 94-103	7.5	14

9	Reply to M. Mo et al. <i>Journal of Clinical Oncology</i> , 2018 , 36, 2452-2453	2.2	
8	Bevacizumab Maintenance Versus No Maintenance During Chemotherapy-Free Intervals in Metastatic Colorectal Cancer: A Randomized Phase III Trial (PRODIGE 9). <i>Journal of Clinical Oncology</i> , 2018 , 36, 674-681	2.2	52
7	Prognostic Value of Sterilized Lymph Nodes After Preoperative Chemoradiotherapy for Patients with ypN0 Rectal Cancer. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1304-1311	3.1	6
6	Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3640-3646	3.1	18
5	Precision medicine for patients with advanced biliary tract cancers: An effective strategy within the prospective MOSCATO-01 trial. <i>European Journal of Cancer</i> , 2017 , 87, 122-130	7.5	75
4	Perioperative chemotherapy with FOLFOX in resectable gastroesophageal adenocarcinoma in real life practice: An AGEO multicenter retrospective study. <i>Digestive and Liver Disease</i> , 2016 , 48, 1498-1502	3.3	4
3	Systemic treatment of advanced hepatocellular carcinoma: from disillusion to new horizons. <i>European Journal of Cancer</i> , 2015 , 51, 327-39	7.5	45
2	Hepatic Resection for Extrahepatic Metastatic Disease: When Is It Reasonable?. <i>Current Colorectal Cancer Reports</i> , 2015 , 11, 78-83	1	
1	Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. <i>Journal of Hepatology</i> , 2012 , 56, 609-17	13.4	130